Document is current

Article History

Received: 23 July 2021

Revised: 26 November 2021

Accepted: 29 November 2021

First Online: 21 January 2022

Declarations

:

: The study was approved by the Danish Data Protection Agency (30–1423/03567) and the Danish Health Data Authority (FSEID: 00003621/DST: 707103).

: The Danish Health and Medicines Authority waived the requirement for patient informed consent to access medical records (case number: 3–3013-896/1).

: We have approval to publish all data presented in the paper.

: Dr. Boesen has served on a scientific advisory board for Teva and has received speaker honoraria for lecturing from Novartis and support for congress participation from Teva, Novartis, and Roche. Dr. Blinkenberg has served on scientific advisory boards for Genzyme, Roche, Biogen, Merck, Novartis, and Teva; has received speaker honoraria from Genzyme, Biogen, Merck, Novartis, Teva, and Roche; has received consulting honoraria from the Danish Multiple Sclerosis Society, Biogen, Teva, Roche, and Merck; and has received funding for travel from Genzyme, Roche, and Biogen. Dr. Thygesen has received honoraria for lecturing from Rigshospitalet (Copenhagen, Denmark), Statistics Denmark, and Sanofi Aventis. Dr. Uldall reports no disclosures. Dr. Born has received speaker honoraria from Novartis and has served on advisory boards for Biogen, Novartis, and Roche. Dr. Magyari has served on the scientific advisory board for Biogen, Sanofi, Teva, Roche, Novartis, and Merck and has received honoraria for lecturing from Biogen, Merck, Novartis, and Sanofi Genzyme and support for congress participation from Biogen, Genzyme, Teva, and Roche. Dr. Eriksson reports no disclosures.